Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?
Q3 2025 Earnings: Beat Expectations and Lifted Guidance Illumina’s latest quarterly report (Q3 FY2025) provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly above Wall Street estimates (~$1.07B) and flat versus the same quarter last year investing.com. While flat growth might not sound impressive, it exceeded Illumina’s own guidance range, marking an improvement in a year where demand had been soft. Adjusted earnings were $1.34 per share, handily beating the ~$1.17 consensus investing.com. CEO Jacob Thaysen noted the team “delivered Q3 results that exceeded the high-end of our guidance… driven by
